Limits...
Antimicrobial Effects and Resistant Regulation of Magnolol and Honokiol on Methicillin-Resistant Staphylococcus aureus.

Kim SY, Kim J, Jeong SI, Jahng KY, Yu KY - Biomed Res Int (2015)

Bottom Line: It was determined that magnolol and honokiol had a synergistic effect with oxacillin against MRSA strain.We concluded that the antibacterial activity of magnolol against MRSA strain is more related to the mecI's pathway and components of the cell wall than mecR1.Therefore, the results obtained in this study suggest that the combination of magnolol and antibiotics could lead to the development of new combination antibiotics against MRSA infection.

View Article: PubMed Central - PubMed

Affiliation: Jeonju Biomaterials Institute, Jeonju, Jeonbuk 561-360, Republic of Korea ; Department of Life Science, Chonbuk National University, Jeonju, Jeonbuk 561-756, Republic of Korea.

ABSTRACT
The antimicrobial killing activity toward methicillin-resistant Staphylococcus aureus (MRSA) has been a serious emerging global issue. In a continuing search for compounds with antibacterial activity against several microorganisms including S. aureus and MRSA, an n-hexane extract of Magnolia officinalis was found to contain magnolol. This compound exhibited potent activity against S. aureus, standard methicillin-susceptible S. aureus (MSSA), and MRSA as well as clinical MRSA isolates. When combined with oxacillin, the antibacterial activities of magnolol and honokiol against the MRSA strain were increased compared to single treatment without antibiotics at 10 µg/mL and 25 µg/mL, respectively. These activities of magnolol and honokiol were dose dependent. Also, magnolol showed synergistic effects with oxacillin against 13 clinical isolates of MRSA. It was determined that magnolol and honokiol had a synergistic effect with oxacillin against MRSA strain. Furthermore, the magnolol inhibited the expression of the resistant genes, mecA, mecI, femA, and femB, in mRNA. We concluded that the antibacterial activity of magnolol against MRSA strain is more related to the mecI's pathway and components of the cell wall than mecR1. Therefore, the results obtained in this study suggest that the combination of magnolol and antibiotics could lead to the development of new combination antibiotics against MRSA infection.

No MeSH data available.


Related in: MedlinePlus

Antimicrobial activities of magnolol (a) and honokiol (b) against Staphylococcus aureus (ATCC 6538), methicillin-resistant Staphylococcus aureus (MRSA, ATCC 33591), Bacillus subtilis (ATCC 6633), and Escherichia coli (ATCC 8739). All strains were cultured at 34°C for 24 h with tryptic soy medium (Difco) under aerobic conditions before the assay. For antibacterial activity test, Mueller-Hinton medium (Difco, Detroit, MI) was used.
© Copyright Policy
Related In: Results  -  Collection

License
getmorefigures.php?uid=PMC4556871&req=5

fig2: Antimicrobial activities of magnolol (a) and honokiol (b) against Staphylococcus aureus (ATCC 6538), methicillin-resistant Staphylococcus aureus (MRSA, ATCC 33591), Bacillus subtilis (ATCC 6633), and Escherichia coli (ATCC 8739). All strains were cultured at 34°C for 24 h with tryptic soy medium (Difco) under aerobic conditions before the assay. For antibacterial activity test, Mueller-Hinton medium (Difco, Detroit, MI) was used.

Mentions: In a continuing search for the compounds with antibacterial activity against several microorganisms including S. aureus, MRSA (ATCC 33591), B. subtilis, and E. coli, an n-hexane extract of M. officinalis showed antimicrobial activities. Magnolol showed antibacterial activities against S. aureus, MRSA, and 13 clinical MRSA isolates (Figure 2(a) and Table 1). According to previous studies [13, 14], magnolol and honokiol showed antibacterial activities against P. acnes (data not shown) and B. subtilis except E. coli (Figure 2). Moreover, the growth of MRSA cultured with magnolol was significantly decreased in the range of 10–25 μg/mL similar to S. aureus. As shown in Figure 2(b), the growth of MRSA cultured with honokiol was significantly decreased in the range of 10–50 μg/mL. However, there was no obvious antimicrobial effect of honokiol against S. aureus, B. subtilis, and E. coli at 50 μg/mL. Magnolol showed better antibacterial activity against S. aureus and MRSA than honokiol. These data suggest that magnolol may be useful to treat S. aureus and MRSA infections.


Antimicrobial Effects and Resistant Regulation of Magnolol and Honokiol on Methicillin-Resistant Staphylococcus aureus.

Kim SY, Kim J, Jeong SI, Jahng KY, Yu KY - Biomed Res Int (2015)

Antimicrobial activities of magnolol (a) and honokiol (b) against Staphylococcus aureus (ATCC 6538), methicillin-resistant Staphylococcus aureus (MRSA, ATCC 33591), Bacillus subtilis (ATCC 6633), and Escherichia coli (ATCC 8739). All strains were cultured at 34°C for 24 h with tryptic soy medium (Difco) under aerobic conditions before the assay. For antibacterial activity test, Mueller-Hinton medium (Difco, Detroit, MI) was used.
© Copyright Policy
Related In: Results  -  Collection

License
Show All Figures
getmorefigures.php?uid=PMC4556871&req=5

fig2: Antimicrobial activities of magnolol (a) and honokiol (b) against Staphylococcus aureus (ATCC 6538), methicillin-resistant Staphylococcus aureus (MRSA, ATCC 33591), Bacillus subtilis (ATCC 6633), and Escherichia coli (ATCC 8739). All strains were cultured at 34°C for 24 h with tryptic soy medium (Difco) under aerobic conditions before the assay. For antibacterial activity test, Mueller-Hinton medium (Difco, Detroit, MI) was used.
Mentions: In a continuing search for the compounds with antibacterial activity against several microorganisms including S. aureus, MRSA (ATCC 33591), B. subtilis, and E. coli, an n-hexane extract of M. officinalis showed antimicrobial activities. Magnolol showed antibacterial activities against S. aureus, MRSA, and 13 clinical MRSA isolates (Figure 2(a) and Table 1). According to previous studies [13, 14], magnolol and honokiol showed antibacterial activities against P. acnes (data not shown) and B. subtilis except E. coli (Figure 2). Moreover, the growth of MRSA cultured with magnolol was significantly decreased in the range of 10–25 μg/mL similar to S. aureus. As shown in Figure 2(b), the growth of MRSA cultured with honokiol was significantly decreased in the range of 10–50 μg/mL. However, there was no obvious antimicrobial effect of honokiol against S. aureus, B. subtilis, and E. coli at 50 μg/mL. Magnolol showed better antibacterial activity against S. aureus and MRSA than honokiol. These data suggest that magnolol may be useful to treat S. aureus and MRSA infections.

Bottom Line: It was determined that magnolol and honokiol had a synergistic effect with oxacillin against MRSA strain.We concluded that the antibacterial activity of magnolol against MRSA strain is more related to the mecI's pathway and components of the cell wall than mecR1.Therefore, the results obtained in this study suggest that the combination of magnolol and antibiotics could lead to the development of new combination antibiotics against MRSA infection.

View Article: PubMed Central - PubMed

Affiliation: Jeonju Biomaterials Institute, Jeonju, Jeonbuk 561-360, Republic of Korea ; Department of Life Science, Chonbuk National University, Jeonju, Jeonbuk 561-756, Republic of Korea.

ABSTRACT
The antimicrobial killing activity toward methicillin-resistant Staphylococcus aureus (MRSA) has been a serious emerging global issue. In a continuing search for compounds with antibacterial activity against several microorganisms including S. aureus and MRSA, an n-hexane extract of Magnolia officinalis was found to contain magnolol. This compound exhibited potent activity against S. aureus, standard methicillin-susceptible S. aureus (MSSA), and MRSA as well as clinical MRSA isolates. When combined with oxacillin, the antibacterial activities of magnolol and honokiol against the MRSA strain were increased compared to single treatment without antibiotics at 10 µg/mL and 25 µg/mL, respectively. These activities of magnolol and honokiol were dose dependent. Also, magnolol showed synergistic effects with oxacillin against 13 clinical isolates of MRSA. It was determined that magnolol and honokiol had a synergistic effect with oxacillin against MRSA strain. Furthermore, the magnolol inhibited the expression of the resistant genes, mecA, mecI, femA, and femB, in mRNA. We concluded that the antibacterial activity of magnolol against MRSA strain is more related to the mecI's pathway and components of the cell wall than mecR1. Therefore, the results obtained in this study suggest that the combination of magnolol and antibiotics could lead to the development of new combination antibiotics against MRSA infection.

No MeSH data available.


Related in: MedlinePlus